Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02867345

PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer

Hormone Refractory Prostate Cancer Clinical Trial

Official title:
A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Castration Resistant Prostate Cancer

Clinical Trial Summary

This study will evaluate the safety of PD-1 knockout engineered T cells in treating castration resistant prostate cancer (CRPC). Blood samples will also be collected for research purposes.

Clinical Trial Description

This is a dose-escalation study of ex-vivo knocked-out, expanded, and selected PD-1 knockout-T cells from autologous origin. Patients are assigned to 1 of 3 treatment groups to determine the maximal tolerant dose. After the lower number of cycles are considered tolerant, an arm of the next higher number of cycles will be open to next patients. Biomarkers and immunological markers are collected and analyzed as well. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02867345
Study type Observational
Source Peking University
Contact
Status Withdrawn
Phase
Start date November 2016
Completion date December 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT00069745 - Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen Phase 3
Completed NCT01260688 - Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel Phase 2
Completed NCT00571675 - A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC) Phase 2
Completed NCT01741116 - Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer Phase 2
Recruiting NCT00795171 - Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer Phase 2
Terminated NCT00525408 - A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer Phase 2
Completed NCT00667199 - BAY88-8223, Does Response Study in HRPC Patients Phase 2
Recruiting NCT02955082 - The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment Phase 2
Recruiting NCT01590498 - Radiotherapy vs Observation for CRPC N/A
Completed NCT01518283 - Study of Weekly Cabazitaxel for Advanced Prostate Cancer Phase 2
Terminated NCT00906243 - RNActive®-Derived Therapeutic Vaccine Phase 1/Phase 2
Terminated NCT00493766 - Safety of LBH589 Alone and in Combination With IV Docetaxel and Prednisone Phase 1
Terminated NCT01083615 - A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Phase 3
Completed NCT00987753 - Study Evaluating the Safety and Tolerability of L-377202 Phase 1/Phase 2
Recruiting NCT02208583 - Molecular Phenotype Changes and Personalized Treatment for CRPC N/A
Completed NCT00928252 - Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer Phase 1/Phase 2
Completed NCT00699751 - A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases Phase 3
Recruiting NCT00411853 - Efficacy of FWGE in Combination With Hormone Therapy for the Treatment of Hormone-Refractory Prostate Cancer Patients Phase 2
Active, not recruiting NCT00448734 - A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer Phase 1/Phase 2
Completed NCT00510718 - A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer Phase 1